Waters Corporation (NYSE:WAT) reported third quarter 2026 financial results on November 3, 2026, disclosing total reported revenue of $1.767 billion and adjusted EPS of $4.10, alongside raised full-year 2026 guidance and the acquisition of MOBILion Systems, Inc.

Key Highlights

  • Total reported revenue: $1.767 billion for Q3 2026, exceeding guidance midpoint by $14 million, according to the filing.
  • Organic revenue growth: 9% as reported and 10% in constant currency, with organic revenue of $871 million compared to $800 million in Q3 2025.
  • Adjusted EPS: $4.10 for Q3 2026, a 21% increase from $3.40 in Q3 2025; GAAP diluted EPS was $0.82.
  • Full-year 2026 guidance raised: Total reported revenue now expected in the range of $6.479 billion to $6.497 billion, a $43 million increase at the midpoint.
  • Full-year 2026 adjusted EPS guidance: Updated to a range of $14.60 to $14.70, representing 11% to 12% year-over-year growth.
  • MOBILion Systems acquisition: The company announced it has acquired MOBILion Systems, Inc., described in the filing as "the pioneer of SLIM high-resolution ion mobility separation technology."
  • 2027 growth framework: Management disclosed it would provide a starting 2027 growth framework during its earnings conference call on November 3, 2026.

Waters Corporation Q3 2026 Divisional Results and Guidance Update

According to the filing, Waters Corporation reported Q3 2026 total revenue of $1.767 billion, comprising $871 million of organic revenue and $896 million from the acquired Biosciences and Diagnostic Solutions businesses. The Analytical Sciences Division delivered reported revenue of $703 million in the quarter, compared to $649 million in Q3 2025, with the filing noting double-digit instrument and chemistry growth. The Biosciences Division reported revenue of $396 million, versus $387 million for the prior year comparable period, with reagents growing high single-digits on a prior year comparable basis.

The Advanced Diagnostics Division, which includes the former BD Diagnostic Solutions business and the Clinical Business Unit, reported Diagnostic Solutions revenue of $500 million compared to $498 million for the prior year comparable period. The Clinical Business Unit contributed $75 million versus $64 million in Q3 2025. The Materials Sciences Division reported revenue of $93 million, up from $87 million in Q3 2025. On a GAAP basis, diluted EPS was $0.82 for Q3 2026, compared to $2.50 in Q3 2025, with the filing attributing the decline to "acquisition-related purchase accounting charges, acquisition-related costs, and restructuring costs."

For the fourth quarter of 2026, the company disclosed expectations for organic constant currency revenue growth in the range of 7.0% to 9.0%, with total reported revenue expected between $1.801 billion and $1.819 billion. Fourth quarter adjusted EPS guidance was set at $4.58 to $4.68, representing 1% to 3% year-over-year growth. The filing also stated that management would outline how "reshoring, synergies and AI-related demand drivers are expected to shape next year's growth" during the earnings call. Regarding MOBILion, the filing noted the acquisition "is expected to broaden the Company's entry into the proteomics market."

What Was Disclosed

Waters Corporation disclosed Q3 2026 results including $1.767 billion in total reported revenue, a 21% increase in adjusted EPS to $4.10, raised full-year 2026 guidance, the completed acquisition of MOBILion Systems, Inc., and a forthcoming 2027 growth framework.